News

Filter

Current filters:

PfizerAfinitor

Renal cell cancer market to rapidly decline from 2019

Renal cell cancer market to rapidly decline from 2019

24-12-2013

The renal cell cancer market is expected to peak at a value of $2.7 billion in 2019, before significantly…

AfinitorAvastinBayerFinancialGlaxoSmithKlineInlytaMarkets & MarketingNexavarNorthern EuropeNovartisOncologyPfizerPharmaceuticalRocheSutentToriselUSAVotrient

Afinitor cleared in USA for advanced RCC

01-04-2009

Swiss drug major Novartis' Afinitor (everolimus) has been approved by the US Food and Drug Administration…

AfinitorAspirinBayerBayerDiovaneverolimusGleevecImatinib MesylateNexavarNovartisPfizerSorafenibSunitinib MalateSutentvalsartan

COMPANY SPOTLIGHT

Menarini

Back to top